Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD8421 |
Synonyms | |
Therapy Description |
AZD8421 selectively inhibits CDK2, potentially leading to decreased Rb1 phosphorylation, cell cycle arrest, and inhibition of proliferation and tumor growth (Cancer Res (2024) 84 (6_Supplement): 5730). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD8421 | AZD-8421|AZD 8421 | CDK2 Inhibitor 31 | AZD8421 selectively inhibits CDK2, potentially leading to decreased Rb1 phosphorylation, cell cycle arrest, and inhibition of proliferation and tumor growth (Cancer Res (2024) 84 (6_Supplement): 5730). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06188520 | Phase Ib/II | AZD8421 + Camizestrant + Palbociclib AZD8421 + Camizestrant + Ribociclib Abemaciclib + AZD8421 + Camizestrant AZD8421 | A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1) | Recruiting | USA | GBR | ESP | AUS | 1 |